The Full Randomized Controlled Trial

Phase 3 is the study the entire program was built to make possible. It enrolls 380 additional participants who, together with the twenty from Phase 2, bring the randomized trial to four hundred veterans, special operators, and athletes in total. (Phase 1's fifty-participant pilot is a standalone study and is not counted in the four hundred.) Participants are randomized across three arms: one receiving structural care at the craniocervical junction, one receiving brain-focused care (hyperbaric oxygen therapy with photobiomodulation), and one receiving both in coordinated sequence. This three-way comparison is what allows the study to answer the question definitively rather than suggestively — revealing not just whether these treatments work, but for whom, and which combination gives each participant the best chance of real recovery.

Because Phase 2 already built and proved the operational machine, Phase 3 requires no startup period. Nearly every dollar flows straight to the front line: to the care itself and to the imaging that documents its effect. Four hundred participants receive care within this trial. The findings it produces could change care for hundreds of thousands more.